combretastatin has been researched along with pyrophosphate in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burchill, SA; Dalal, S | 1 |
| Cai, YC; Xian, LJ; Zou, Y | 1 |
| Azzariti, A; Gnoni, A; Numico, G; Paradiso, A; Porcelli, L; Quatrale, AE | 1 |
| Elming, PB; Horsman, MR; Nielsen, PS; Wittenborn, TR | 1 |
2 review(s) available for combretastatin and pyrophosphate
| Article | Year |
|---|---|
[Advances in the study of the anti-tumor activity of small molecule vascular disrupting agents].
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Bibenzyls; Diphosphates; Endothelial Cells; Humans; Molecular Structure; Neoplasms; Neovascularization, Pathologic; Oligopeptides; Organophosphorus Compounds; Serine; Stilbenes; Tubulin Modulators; Xanthones | 2010 |
New vascular disrupting agents in upper gastrointestinal malignancies.
Topics: Angiogenesis Inhibitors; Animals; Bibenzyls; Diphosphates; Gastrointestinal Neoplasms; Humans; Neovascularization, Pathologic; Organophosphorus Compounds; Serine; Stilbenes; Upper Gastrointestinal Tract | 2014 |
2 other study(ies) available for combretastatin and pyrophosphate
| Article | Year |
|---|---|
Preclinical evaluation of vascular-disrupting agents in Ewing's sarcoma family of tumours.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bibenzyls; Bone Neoplasms; Cell Proliferation; Diphosphates; Disease Models, Animal; Doxorubicin; Drug Evaluation, Preclinical; Mice; Mice, Nude; Necrosis; Neoplasm Transplantation; Neovascularization, Pathologic; Sarcoma, Ewing; Stilbenes | 2009 |
Tumors Resistant to Checkpoint Inhibitors Can Become Sensitive after Treatment with Vascular Disrupting Agents.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bibenzyls; CTLA-4 Antigen; Diphosphates; Disease Progression; Drug Resistance, Neoplasm; Female; Immune Checkpoint Inhibitors; Male; Mammary Neoplasms, Animal; Mice; Mice, Inbred C3H; Neovascularization, Pathologic; Stilbenes; Treatment Outcome | 2020 |